Results 21 to 30 of about 5,389 (186)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis [PDF]

, 2023
Purpose: This meta-analysis summarizes the incidence of treatment-related adverse events (AE) of BRAFi and MEKi. Methods: A systematic search of Medline/PubMed was conducted to identify suitable articles published in English up to 31 December 2021.
Bergnach M., Garutti M., Palmero L., Pizzichetta M. A., Polesel J., Puglisi F.   +5 more
core   +4 more sources

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Case Reports in Oncology, 2022
Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy.
Yumi Kambayashi, Kentaro Ohuchi, Hiromu Chiba, Erika Tamabuchi, Tasuku Nagasawa, Yoshihide Asano, Taku Fujimura   +6 more
doaj   +1 more source

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System

Frontiers in Oncology, 2023
IntroductionNew oral tyrosine kinase inhibitors (TKIs) are approved for metastatic colorectal cancer (mCRC). The aim of this study was to assess the neuropsychiatric adverse drug reactions (ADRs) of these drugs reported in the FDA Adverse Event Reporting
Maria Antonietta Barbieri, Giulia Russo, Emanuela Elisa Sorbara, Giuseppe Cicala, Tindara Franchina, Mariacarmela Santarpia, Desirèe Speranza, Edoardo Spina, Nicola Silvestris   +8 more
doaj   +1 more source

A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

Molecules, 2022
The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi™, ENF) plus binimetinib (Mektovi®, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600 ...
Mohamed M. Hefnawy, Mohammed M. Alanazi, Abdullah M. Al-Hossaini, Abdulaziz I. Alnasser, Adel S. El-Azab, Yousef A. Bin Jardan, Mohamed W. Attwa, Manal A. El-Gendy   +7 more
doaj   +1 more source

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer [PDF]

, 2023
Antitumor efficacy; Chemotherapy; Colorectal cancerEficàcia antitumoral; Quimioteràpia; Càncer colorectalEficacia antitumoral; Quimioterapia; Cáncer colorrectalPurpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory ...
De Falco, Vincenzo, Della Corte, Carminia Maria, Lee, Hey Min, MARTINI, Giulia, Napolitano, Stefania, Tabernero, Josep, Woods, Melanie   +6 more
core   +4 more sources

Emerging treatment options for BRAF-mutant colorectal cancer. [PDF]

, 2018
The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments.
Atreya, Chloe E, Ursem, Carling, Van Loon, Katherine   +2 more
core   +2 more sources

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation

Molecules, 2021
The concurrent use of oral encorafenib (Braftovi, ENF) and binimetinib (Mektovi, BNB) is a combination anticancer therapy approved by the United States Food and Drug Administration (USFDA) for patients with BRAFV600E/V600K mutations suffering from ...
Mohamed W. Attwa, Hany W. Darwish, Nasser S. Al-Shakliah, Adnan A. Kadi   +3 more
doaj   +1 more source

In vivo E2F reporting reveals efficacious schedules of MEK1/2–CDK4/6 targeting and mTOR–s6 resistance mechanisms [PDF]

, 2018
Targeting cyclin-dependent kinases 4/6 (CDK4/6) represents a therapeutic option in combination with BRAF inhibitor and/or MEK inhibitor (MEKi) in melanoma; however, continuous dosing elicits toxicities in patients. Using quantitative and temporal in vivo
Aplin, Andrew E., Cheng, Phil F., Chervoneva, Inna, Davies, Michael A., Dummer, Reinhard, Ertel, Adam, Fortina, Paolo, Hookim, Kim, Kleiber, Ines, Kwong, Lawrence N., Levesque, Mitch P., Nikbakht, Neda, Patel, Prem, Purwin, Timothy J., Teh, Jessica L. F.   +14 more
core   +1 more source

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database

Biomedicines, 2023
Background: this study assessed the nephrotoxicity of regorafenib (REG) and encorafenib (ENC) in metastatic colorectal cancer (mCRC) through an analysis of reports from the US Food and Drug Administration’s Adverse Event Reporting System (FAERS) database.
Giulia Russo, Maria Antonietta Barbieri, Emanuela Elisa Sorbara, Giuseppe Cicala, Tindara Franchina, Mariacarmela Santarpia, Nicola Silvestris, Edoardo Spina   +7 more
doaj   +1 more source